Gérard Soula is reappointed as Chairman of the Board of Directors ;
Olivier Soula’s primary near-term objective is to sign a partnership on M1Pram and renegotiate agreements with Company’s main lenders.
6:00 pm CEST – Adocia (Euronext Paris: FR0011184241 – ADOC), a clinical-stage biopharmaceutical Company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and other metabolic diseases, announced today the appointment of Olivier Soula as Chief Executive Officer of Adocia, by decision of the Board of Directors which met on May 11, 2023, in Paris. Olivier Soula succeeds Gérard Soula, whose term as Chairman of the Board of Directors was renewed.